Iovance Operating Cycle from 2010 to 2026
| IOVA Stock | USD 2.64 0.03 1.15% |
Operating Cycle | First Reported 2010-12-31 | Previous Quarter 351.8 | Current Value 387.35 | Quarterly Volatility 24.38009258 |
Check Iovance Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Iovance Biotherapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 52.7 M, Interest Expense of 3.6 M or Selling General Administrative of 32.1 M, as well as many indicators such as Price To Sales Ratio of 14.28, Dividend Yield of 0.1 or PTB Ratio of 3.3. Iovance financial statements analysis is a perfect complement when working with Iovance Biotherapeutics Valuation or Volatility modules.
Iovance | Operating Cycle | Build AI portfolio with Iovance Stock |
Analyzing Iovance Biotherapeutics's Operating Cycle over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Operating Cycle has evolved provides context for assessing Iovance Biotherapeutics's current valuation and future prospects.
Latest Iovance Biotherapeutics' Operating Cycle Growth Pattern
Below is the plot of the Operating Cycle of Iovance Biotherapeutics over the last few years. It is Iovance Biotherapeutics' Operating Cycle historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Iovance Biotherapeutics' overall financial position and show how it may be relating to other accounts over time.
| Operating Cycle | 10 Years Trend |
|
Operating Cycle |
| Timeline |
Iovance Operating Cycle Regression Statistics
| Arithmetic Mean | 389.53 | |
| Geometric Mean | 388.72 | |
| Coefficient Of Variation | 6.26 | |
| Mean Deviation | 14.53 | |
| Median | 398.36 | |
| Standard Deviation | 24.38 | |
| Sample Variance | 594.39 | |
| Range | 92.4403 | |
| R-Value | (0.49) | |
| Mean Square Error | 480.72 | |
| R-Squared | 0.24 | |
| Significance | 0.04 | |
| Slope | (2.37) | |
| Total Sum of Squares | 9,510 |
Iovance Operating Cycle History
About Iovance Biotherapeutics Financial Statements
Iovance Biotherapeutics stakeholders use historical fundamental indicators, such as Iovance Biotherapeutics' Operating Cycle, to determine how well the company is positioned to perform in the future. Although Iovance Biotherapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Iovance Biotherapeutics' assets and liabilities are reflected in the revenues and expenses on Iovance Biotherapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Iovance Biotherapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Operating Cycle | 351.80 | 387.35 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Iovance Biotherapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Iovance Biotherapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Iovance Biotherapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Iovance Biotherapeutics Stock:Check out the analysis of Iovance Biotherapeutics Correlation against competitors. For information on how to trade Iovance Stock refer to our How to Trade Iovance Stock guide.You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Iovance Biotherapeutics. Market participants price Iovance higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Iovance Biotherapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (1.19) | Revenue Per Share | Quarterly Revenue Growth 0.152 | Return On Assets | Return On Equity |
Understanding Iovance Biotherapeutics requires distinguishing between market price and book value, where the latter reflects Iovance's accounting equity. The concept of intrinsic value - what Iovance Biotherapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Iovance Biotherapeutics' price substantially above or below its fundamental value.
Please note, there is a significant difference between Iovance Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Iovance Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Iovance Biotherapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.